<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of this study was to assess pregnancy outcome in women with a history of refractory <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo>-associated pregnancy loss(es) who were treated with early low-dose <z:chebi fb="2" ids="8378">prednisolone</z:chebi> in addition to aspirin and <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Eighteen women with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> who had refractory pregnancy loss(es) were given <z:chebi fb="2" ids="8378">prednisolone</z:chebi> (10 mg) from the time of their positive pregnancy test to 14 weeks' gestation </plain></SENT>
<SENT sid="2" pm="."><plain>Before low-dose <z:chebi fb="2" ids="8378">prednisolone</z:chebi> was given as treatment, 4 (4%) of 97 pregnancies had resulted in live births </plain></SENT>
<SENT sid="3" pm="."><plain>Among 23 pregnancies supplemented with <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, 9 women had 14 live births (61%), including 8 uncomplicated pregnancies </plain></SENT>
<SENT sid="4" pm="."><plain>The remainder were complicated by <z:hpo ids='HP_0001622'>preterm delivery</z:hpo>, <z:e sem="disease" ids="C0032914" disease_type="Disease or Syndrome" abbrv="PEE|PREG1|PEE1">preeclampsia</z:e>, and/or <z:hpo ids='HP_0001511'>small-for-gestational-age infants</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>There were 8 first-trimester <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> and 1 <z:mp ids='MP_0009668'>ectopic pregnancy</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>There were no fetal <z:hpo ids='HP_0011420'>deaths</z:hpo> after 10 weeks' gestation and no evidence of maternal morbidity </plain></SENT>
<SENT sid="7" pm="."><plain>The addition of first-trimester low-dose <z:chebi fb="2" ids="8378">prednisolone</z:chebi> to conventional treatment is worthy of further assessment in the management of refractory <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo>-related pregnancy loss(es), although complications remain elevated </plain></SENT>
</text></document>